The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | Evaluating the role of ADCs in oncogenic-addicted NSCLC
Giannis Mountzios, MD, Henry Dunant Hospital, Athens, Greece, comments on how antibody-drug conjugates (ADCs) fit in the treatment algorithm for oncogene-addicted non-small cell lung cancer (NSCLC). ADCs are currently being assessed in the second-line setting, particularly in patients who have failed targeted agents and platinum-based chemotherapy. ADCs could also be implemented in the first-line setting in the future, potentially in combination with other targeted therapies, although the optimal combination and approach need to be further defined. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So for the time being, antibody drug conjugates are mainly involved, actively involved in clinical trials in the second line setting. So in patients with oncogene-addicted non-small cell cancer in the second and beyond treatment setting, after targeted agents in the first line setting have failed, and in some of those trials also after platinum-based chemotherapy. So most of these ADCs are now being evaluated in clinical trials in pre-treated patients after targeted treatment and chemotherapy, platinum-based chemotherapy...
So for the time being, antibody drug conjugates are mainly involved, actively involved in clinical trials in the second line setting. So in patients with oncogene-addicted non-small cell cancer in the second and beyond treatment setting, after targeted agents in the first line setting have failed, and in some of those trials also after platinum-based chemotherapy. So most of these ADCs are now being evaluated in clinical trials in pre-treated patients after targeted treatment and chemotherapy, platinum-based chemotherapy. But we really hope, we believe that the next step to move forward will be to implement those ADCs in the first-line setting in patients with oncogene-addicted tumours, probably with combinations with EGFR, TKIs, and kinase inhibitors, or ALK inhibitors, or other types of oncogenic alterations. and it remains to be defined, to be clarified, which is the optimal combination, the optimal way to move forward by using them in the first line setting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
